The longevity sector is evolving, with a notable shift from a traditional 'sickcare' model to a proactive approach that emphasizes prevention and management of aging-related diseases.

Key players in this emerging field include Cyclarity Therapeutics, BioAge Labs, Life Biosciences, Unity Biotechnology, and Insilico Medicine, each pioneering innovative therapies targeting various mechanisms of aging.

Aging disease management encompasses clinical interventions aimed at alleviating symptoms of prevalent diseases among older adults, such as cardiovascular issues, diabetes, and neurodegenerative disorders.

Cyclarity Therapeutics is developing drugs designed to remove harmful substances from the body, which may help slow the progression of age-related diseases.

Unity Biotechnology is focused on creating senolytic medicines that target and eliminate senescent cells, potentially addressing conditions like osteoarthritis.

Insilico Medicine leverages artificial intelligence for drug discovery, targeting the root causes of aging-related diseases, including ALS and Alzheimer’s.

Emerging technologies such as AI and machine learning are increasingly being utilized to identify drug candidates and optimize treatment plans for aging-related diseases.

BioAge Labs is concentrating on therapies for obesity and metabolic diseases, particularly those linked to neuroinflammation associated with aging, in collaboration with Novartis.

Life Biosciences aims to develop cellular rejuvenation therapies that target age-related diseases through the process of epigenetic reprogramming.

As the global population ages, investment opportunities in healthcare are expanding, driven by the demand for effective disease management solutions.

Some companies are poised to advance within the Ten Levels of Longevity framework, focusing on targeted aging disease reversal and prevention therapeutics.